

Hepatitis C medication coverage and treatment

UnitedHealthcare Community Plan of Texas is committed to supporting you in delivering the best health care experience possible for our members who have been diagnosed with or are at risk of exposure to hepatitis C. New hepatitis C screening, testing and treatments are available for members of Medicare-Medicaid Plan (MMP), STAR, STAR Kids and STAR+PLUS plans.

Please help us ensure members are screened and receive early treatment for hepatitis C or given prevention education.

Coverage

Coverage for hepatitis C treatment is available for all Medicaid recipients.

Screening

The following individuals should be screened for hepatitis C:

- Those who are 18 years and older (for one-time testing)
- Pregnant women
- Anyone who asks for the test, regardless of age or disclosure of risk

Testing

- Consider ordering a hepatitis C virus (HCV) antibody test with reflex to quantitative HCV RNA test (CPT® code 86803), which automatically tests for HCV RNA on the same sample if the HCV antibody test returns positive
- We cover the test cost if the patient receives it through Quest Diagnostics or Labcorp

Repeat testing may be necessary for those with risk exposures and other conditions. For more information, please see the **Chronic HCV Infection: Screening Assessment Guide** from AbbVie.



Questions?

For chat options and contact information, visit UHCprovider.com/contactus.

Treatment

For many people, hepatitis C can be treated and cured with an 8- to 12-week medication treatment. On Jan. 1, 2023, Texas Medicaid made Mavyret® (glecaprevir/pibrentasvir) the preferred direct-acting antiviral (DAA) to treat hepatitis C. Mavyret can stop the hepatitis C virus from multiplying and has a cure rate of 95%. For information, please visit mavyret.com. To ensure that your patients are following the treatment plan, it may be necessary to follow up with them.

As you develop a treatment plan, please consider that Mavyret is:

- Used to treat adults and children 3 years of age and older with chronic HCV
- **Available to all Medicaid recipients for DAA treatment, regardless of their METAVIR fibrosis score**
- **Available without prior authorization or medication screening requirements**
- **Able to be prescribed by any Medicaid provider for an 8-week treatment duration, though providers may write refills for a more extended period if needed. Patients no longer need to request additional refills during their treatment.**

For more treatment information, please see the AbbVie [Chronic HCV Infection: On-treatment Monitoring Guide](#).



Additional resources

- Centers for Disease Control and Prevention hepatitis C [Professional Resources](#) page
- U.S. Department of Health and Human Services [Viral Hepatitis](#) page
- AbbVie Medical Affairs [Provider Resources](#) page

CPT is a registered trademark of the American Medical Association.